Latest news with #Baird
Business Insider
10 hours ago
- Business
- Business Insider
Baird Upgrades nCino (NCNO) to Outperform, Sees 29%
Shares of nCino (NCNO), a global provider of cloud-based software solutions in the financial services industry, are gaining momentum after an upgrade from Baird. Five-star analyst Joseph Vruwink raised the firm's rating from Neutral to Outperform and lifted the price target to $38 from $30. That implies a potential upside of about 29% from the stock's recent price of $29. Vruwink cited improved macro conditions, new product traction, and go-to-market execution as reasons for a more constructive view. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week. Confidence Returns as nCino Resets and Rebounds According to Baird, management appears increasingly confident, following a financial reset earlier this year that reset investor expectations. The analyst believes nCino could deliver earnings beats in the coming quarters and sees the current setup as one of the best in years. Management meetings also highlighted stronger internal execution and increased enthusiasm around product updates. Vruwink's bullish sentiment comes as a respite for nCino, which has had a tough year, down 12% year-to-date. Most of the decline occurred in March, following the company's reset of its financial outlook for fiscal 2026. Since then, the stock has bounced back and now trades within 5% to 10% of its pre-reset levels. Vruwink believes nCino is in the early stages of regaining investor confidence. The firm expects subscription growth to return to double digits and management to reach its goal of achieving the Rule of 40, which combines profit margin and revenue growth. While the stock still faces hurdles, including cautious sentiment across small-cap software names, Baird sees a favorable risk-reward at current levels. For now, the market will be watching for signs that nCino can deliver consistent execution and meet its growth targets. Is nCino a Good Stock to Buy? On the Street, analysts are split over nCino, as it is rated Moderate Buy based on 17 analyst reviews, with 7 Buy and 10 Hold ratings. The average Wall Street price target is $31.38, indicating a 5% upside. No analysts currently rate the stock a Sell.
Yahoo
12 hours ago
- Business
- Yahoo
Why Shopify Was Climbing Today
Needham weighed in with a buy rating on Shopify, and Baird raised its price target. The company has performed well in an uncertain consumer environment. Analysts are expecting another round of solid growth when the company reports second-quarter earnings in a few weeks. 10 stocks we like better than Shopify › Shares of Shopify (NASDAQ: SHOP) were moving higher today after the e-commerce software superstar picked up some new fans on Wall Street. Shopify scored a buy rating from Needham, and another analyst raised their price target on the growth stock. As of 1:48 p.m. ET, the stock was up 4.2% on the news. Needham became the latest research firm to weigh in positively on Shopify, calling the stock a buy with a price target of $135. The firm observed that Shopify was in the middle of a durable growth cycle, benefiting from continuing growth in consumer spending, despite weak sentiment, and it's likely to benefit from the recently signed U.S. tax bill. Additionally, Baird raised its price target on the stock from $110 to $120, and maintained an outperform rating as analyst Colin Sebastian said that its merchant business remains healthy despite headwinds on its monthly recurring revenue. Shopify has a lot of exposure to the business cycle and broader consumer demand, but its continued growth in the face of concerns about a trade war is a positive sign. The opportunity in front of the company still seems sizable as it innovates and invests in AI, and continues to attract new merchants to the platform. Investors will want to pay attention tomorrow morning when the June Consumer Price Index is released, as that could move the stock. Investors are still anxious to see if tariffs have had any impact on prices thus far. A few weeks later, Shopify will report second-quarter earnings. Analysts expect revenue to jump 24.5% to $2.55 billion, and see adjusted earnings per share improving from $0.26 to $0.29. Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 14, 2025 Jeremy Bowman has positions in Shopify. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. Why Shopify Was Climbing Today was originally published by The Motley Fool
Bloomberg
a day ago
- Business
- Bloomberg
A Rare JPM Bear on Why it's Time to Sell
David George, Baird Senior Research Analyst, says he sees a dichotomy between very high expectations yet very good fundamentals in JPMorgan. (Source: Bloomberg)
Yahoo
a day ago
- Business
- Yahoo
Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series
WATERTOWN, Mass., July 15, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at A replay of the webcast will be available following the event and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
2 days ago
- Hamilton Spectator
‘Obscene brutality': Baseball-bat killer gets life term despite constitutional ruling
The B.C. Supreme Court has sentenced a man to life in prison without parole eligibility for 25 years for beating his ex-girlfriend to death with a baseball bat as she slept beside her young daughter in 2021. The court ruling posted Monday says Luciano Mariani's killing of Caroline Bernard in her home in Bowser, B.C., was a crime of 'obscene brutality' that was planned in advance for months. Mariani had pleaded guilty to first-degree murder, but filed a successful constitutional challenge against a provision in Canada's Criminal Code preventing those convicted of the crime from applying for parole for 25 years. The court agreed in January that it was unconstitutional to treat all offenders convicted of first-degree murder the same, but Justice Robin Baird says in sentencing that there was 'nothing disproportionate about the mandatory penalty' for Mariani. Baird's ruling says the murder was 'exceptionally violent,' cold-blooded and against a vulnerable former intimate partner. Judge Baird's ruling says Mariani may apply to reduce his parole eligibility period after 15 years, but there's no 'guarantee that it will be granted.' 'This was, it goes quite without saying, a crime of obscene brutality with maximally aggravating features fully justifying the severe penalty that the law requires me to impose,' Baird's ruling says. 'The damage that you have done to Ms. Bernard's family and friends is profound and permanent. The magnitude of the insult and injury that you have inflicted upon our local community is enormous. And first and foremost, you have brutally extinguished the life of a fine young woman who was beloved by all who knew her.' Baird said murderers serving life sentences get denied parole for many years after becoming eligible to apply, 'and of course the most serious, dangerous and high‑risk offenders never succeed in getting it.' This report by The Canadian Press was first published July 14, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
